Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)
Services
Services
Date issued
2013Journal title
ZEITSCHRIFT FUR RHEUMATOLOGIE
Type of content
Publicación de congreso
